Properties (61)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:Company
|
gptkbp:activeDuring |
dexamethasone
|
gptkbp:administrativeDivision |
up to 30 days
once per eye conjunctival sac intraocular insertion |
gptkbp:applicationStatus |
approved
|
gptkbp:clinicalTrials |
gptkb:United_States
gptkb:Ocular_Therapeutix,_Inc. available online positive Phase 3 reduces inflammation Phase 1, Phase 2, Phase 3 randomized controlled trial demonstrated efficacy published in medical journals various sites improved symptoms recommended for use ocular surgery recovery |
gptkbp:community_service |
efficacy and safety
available through pharmacies |
gptkbp:communityPartnerships |
none disclosed
|
gptkbp:customerFeedback |
generally positive
|
gptkbp:delivers |
insert
|
gptkbp:developedBy |
gptkb:Ocular_Therapeutix,_Inc.
|
gptkbp:drugInterdiction |
2018-06-28
corticosteroid insertable hydrogel stable for 30 days sustained-release technology |
gptkbp:exportMarkets |
ongoing
|
gptkbp:formulation |
sustained-release hydrogel
|
gptkbp:hasCompetitors |
other dry eye treatments
|
gptkbp:hasPopulation |
adults
|
gptkbp:healthcare |
high
ongoing |
https://www.w3.org/2000/01/rdf-schema#label |
Ocular Therapeutix OTX-TP
|
gptkbp:impact |
up to 30 days
reduced symptoms of dry eye single insertion |
gptkbp:mandates |
post-surgical inflammation
|
gptkbp:market |
2018
achieved |
gptkbp:marketedAs |
brand name Dextenza
|
gptkbp:patentStatus |
patented
|
gptkbp:productionCompany |
commercialized
|
gptkbp:purpose |
ocular inflammation management
|
gptkbp:regulatoryBody |
gptkb:FDA
|
gptkbp:research |
private investment
|
gptkbp:research_areas |
ophthalmology
|
gptkbp:researchAreas |
sustained drug delivery systems
|
gptkbp:researchFocus |
ocular drug delivery
|
gptkbp:researchInterest |
peer-reviewed journals
none disclosed |
gptkbp:route |
topical
|
gptkbp:safetyFeatures |
generally well tolerated
|
gptkbp:sideEffect |
eye irritation
|
gptkbp:triggerType |
anti-inflammatory
|
gptkbp:usedFor |
treatment of dry eye disease
|